British pharmacy chain Boots has set a deadline of 24 February to receive indicative bids from potential investors.
The company is being sold as part of an auction process led by investment banking and financial services firm Goldman Sachs.
The Walgreens Boots Alliance (WBA) initiated the sales process last month.
Citing insiders, Bloomberg reported that buyout firm Sycamore Partners is exploring bids for Boots.
This business could also draw interest from TDR Capital and the Issa brothers, as well as a consortium of CVC Capital Partners, Bain Capital and Apollo.
Sycamore Partners, Bain Capital, Apollo and CD&R declined to comment, while TDR and CVC were not available for comments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Reuters reported that Boots could be valued at up to £8bn ($10bn).
The company operates more than 2,200 stores across the UK under various brands, including No7 Beauty Company, employing around 51,000 people in total.
It also operates in Ireland, Norway, the Netherlands and Thailand.
The divestiture would end the WBA, which was formed in 2014 after Walgreens took over Boots.
Besides the sale, Walgreens is reportedly considering an initial public offering (IPO) of Boots if it fails to secure a buyer.
The company has backed Boots since 2012.
CD&R had initially planned to combine its supermarket chain Morrison’s with Boots if a bid for Boots was successful, but this has been blocked by the Competition and Markets Authority (CMA).
The CMA is currently reviewing CD&R’s takeover of Morrison’s, which was announced in October last year.
Last month, the WBA reported that its sales from continuing operations in the first quarter (Q1) of the fiscal year 2022 (FY22) were $33.9bn, a 7.8% increase from the $31.4bn recorded in Q1 2021.
The company generated an operating income of $1.3bn in Q1 2022 after registering a loss of $535m in the same period of last year.